NGM NGM Biopharmaceuticals Inc.

Biotech Analyst Ratings

Latest News

1. 12 May 2022 NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

   --Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA^®--

   --All three of NGM Bio's wholly-owned myeloid reprogramming product candidates –NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, NGM831, an ILT3 antagonist antibody, and NGM438 – are now in the clinic--

   --NGM Bio is implementing a biomarker strategy across NGM707, NGM831 and NGM438 designed to assess target engagement and guide dose selection, to demonstrate proof-of-mechanism and to potentially enable patient selection strategies--

   SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM…

   View Full Article
2. 05 May 2022 NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results

   • Initiated Phase 1/1b clinical trial of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA^® (pembrolizumab), for the treatment of patients with advanced solid tumors
     
   • Presented preclinical research for NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, NGM831 and NGM438, a LAIR1 antagonist product candidate, at the American Association for Cancer Research (AACR) 2022 Annual Meeting

   SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the quarterly…

   View Full Article
3. 20 April 2022 NGM Bio to Participate in Upcoming Investor Conferences

   SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming virtual investor conferences.
   

   Raymond James LILRB/ILT Symposium
   Tuesday, April 26, 2022, 1:30 pm ET

   B. Riley Securities' 2022 Virtual Neurology & Ophthalmology Conference
   Thursday, April 28, 2022, 10:30 am ET

   Live webcasts of the presentations will be available under the Investors and Media section of NGM Bio's website at https://ir.ngmbio.com/events-presentations…

   View Full Article
4. 20 April 2022 NGM Bio to Host the Second of Four Virtual R&D Events on April 27, 2022

   SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the second of four virtual R&D events on Wednesday, April 27, 2022, from 11:00 am – 12:30 pm ET. This four-part series of virtual webcasts, titled the "Explorer Series", will highlight the company's work as explorers on the frontier of life-changing science.

   The second event will focus on NGM Bio's myeloid reprogramming programs targeting stromal checkpoints: NGM831, an ILT3 antagonist antibody product candidate, and NGM438, a LAIR1 antagonist antibody product candidate. ILT3 and LAIR1 are members…

   View Full Article
5. 08 April 2022 NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio

   • ILT2, ILT4, ILT3 and LAIR1 are myeloid checkpoints that may play a central role in establishing an immune-suppressive state in the tumor microenvironment
     
   • NGM707, NGM831 and NGM438 are all engineered to release myeloid checkpoints and reprogram myeloid cells to reverse immune suppression and enhance immune response in tumors
   • NGM707 and NGM831 are currently in the clinic, and NGM438 is anticipated to enter the clinic this quarter
     

   SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided additional detail today on two late-breaking poster presentations it will give on Wednesday…

   View Full Article